A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis.

Trial Profile

A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Aug 2014

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Apr 2012 Planned end date changed from 1 Dec 2011 to 1 Nov 2012 as reported by ClinicalTrials.gov.
    • 26 Apr 2011 Actual initiation date (March 2010) added as reported by ClinicalTrials.gov.
    • 26 Apr 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top